BioMediTech at the University of Tampere (UTA) is part of the joint BioMediTech institute of the UTA and Tampere University of Technology (TUT).
BioMediTech is a joint institute of the University of Tampere (UTA) and Tampere University of Technology (TUT). Its research activities cover diverse areas, including cell and molecular biology, genetics, biomaterials, biosensors, computational systems, biotechnology, biomedical engineering, and regenerative medicine.
At BioMediTech, UTA and TUT educate together top-level experts with multidisciplinary skills in life sciences for the demands of both academia and industry. The students apply to and their studies are administered by either UTA or TUT.
These pages concentrate on the BioMediTech activities administered by the University of Tampere. The issues concerning the joint institute can be found on the institute's webpages.
There is a new FiDiPro at BioMediTech. Malin Flodström-Tullberg has started her FiDiPro period at BioMediTech in the beginning of 2015. Her work here concentrates on type 1 diabetes and enteroviruses. Enteroviruses are among the most common viruses affecting humans. They cause a wide range of diseases, and recent studies indicate enteroviruses being responsible for type 1 diabetes. This project will develop novel diagnostics, vaccines and therapies for the prevention and control of type 1 diabetes and other enterovirus-induced diseases. Read more on Malin Flodström-Tullberg on Karolinska Institute's website.